Comparison of overall survival between antiviral‐induced viral suppression and inactive phase chronic hepatitis B patients

Summary Nucleot(s)ide analogues (NAs) reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. However, the risk of HCC is reportedly higher for NA‐treated patients than for patients in the inactive CHB phase. This study aimed to compare the long‐term outcomes of CHB...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2018-10, Vol.25 (10), p.1161-1171
Main Authors: Cho, Y. Y., Lee, J.‐H., Chang, Y., Nam, J. Y., Cho, H., Lee, D. H., Cho, E. J., Yu, S. J., Lee, J. M., Kim, Y. J., Yoon, J.‐H.
Format: Article
Language:English
Subjects:
Antiviral agents
antiviral treatment
chronic hepatitis B
Cirrhosis
Deoxyribonucleic acid
DNA
Hepatitis
Hepatitis B
Hepatocellular carcinoma
Interferon
Liver
Liver cancer
Liver cirrhosis
Patients
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Nucleot(s)ide analogues (NAs) reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. However, the risk of HCC is reportedly higher for NA‐treated patients than for patients in the inactive CHB phase. This study aimed to compare the long‐term outcomes of CHB patients with NA‐induced viral suppression and those of patients with inactive CHB. This retrospective study involved 1118 consecutive CHB patients whose HBV DNA level was continuously
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.12927